Eli Lilly and Company’s (LLY) Overweight Rating Reaffirmed at Cantor Fitzgerald

Cantor Fitzgerald reissued their overweight rating on shares of Eli Lilly and Company (NYSE:LLYFree Report) in a research note issued to investors on Thursday morning, Benzinga reports. The brokerage currently has a $630.00 target price on the stock.

A number of other research firms have also recently issued reports on LLY. UBS Group reissued a buy rating and issued a $710.00 target price (up from $612.00) on shares of Eli Lilly and Company in a research note on Friday, October 20th. Bank of America raised their price target on shares of Eli Lilly and Company from $600.00 to $700.00 in a research note on Friday, October 6th. JPMorgan Chase & Co. reissued an overweight rating on shares of Eli Lilly and Company in a research report on Wednesday, November 8th. Barclays raised their target price on shares of Eli Lilly and Company from $630.00 to $680.00 and gave the company an overweight rating in a research report on Tuesday, January 23rd. Finally, Citigroup raised their target price on shares of Eli Lilly and Company from $525.00 to $675.00 and gave the company a buy rating in a research note on Monday, October 23rd. One analyst has rated the stock with a sell rating, two have given a hold rating and seventeen have issued a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of Moderate Buy and an average target price of $589.90.

Read Our Latest Analysis on Eli Lilly and Company

Eli Lilly and Company Stock Performance

Shares of LLY stock opened at $667.65 on Thursday. The stock has a 50-day moving average of $606.79 and a 200-day moving average of $572.66. Eli Lilly and Company has a one year low of $309.20 and a one year high of $672.61. The stock has a market cap of $633.81 billion, a PE ratio of 120.95, a price-to-earnings-growth ratio of 2.16 and a beta of 0.32. The company has a debt-to-equity ratio of 1.59, a current ratio of 1.05 and a quick ratio of 0.82.

Eli Lilly and Company (NYSE:LLYGet Free Report) last posted its earnings results on Thursday, November 2nd. The company reported $0.10 earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.18. Eli Lilly and Company had a net margin of 15.55% and a return on equity of 48.12%. The company had revenue of $9.50 billion for the quarter, compared to analyst estimates of $8.88 billion. As a group, sell-side analysts expect that Eli Lilly and Company will post 6.34 earnings per share for the current year.

Eli Lilly and Company Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, March 4th. Shareholders of record on Thursday, February 15th will be given a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 0.78%. The ex-dividend date of this dividend is Wednesday, February 14th. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.13. Eli Lilly and Company’s payout ratio is currently 81.88%.

Insider Activity

In related news, major shareholder Lilly Endowment Inc sold 34,538 shares of the stock in a transaction that occurred on Tuesday, January 9th. The shares were sold at an average price of $631.81, for a total value of $21,821,453.78. Following the completion of the transaction, the insider now owns 99,719,884 shares of the company’s stock, valued at approximately $63,004,019,910.04. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In the last three months, insiders have sold 195,055 shares of company stock worth $125,254,657. Corporate insiders own 0.13% of the company’s stock.

Hedge Funds Weigh In On Eli Lilly and Company

Institutional investors and hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. increased its holdings in Eli Lilly and Company by 0.9% in the third quarter. Vanguard Group Inc. now owns 70,575,602 shares of the company’s stock valued at $37,908,273,000 after purchasing an additional 659,838 shares during the period. State Street Corp increased its position in shares of Eli Lilly and Company by 1.9% during the second quarter. State Street Corp now owns 33,878,417 shares of the company’s stock worth $15,888,300,000 after buying an additional 642,274 shares during the period. Geode Capital Management LLC lifted its holdings in Eli Lilly and Company by 2.3% in the second quarter. Geode Capital Management LLC now owns 15,205,501 shares of the company’s stock valued at $7,111,568,000 after buying an additional 338,077 shares during the period. Morgan Stanley boosted its position in Eli Lilly and Company by 0.7% during the third quarter. Morgan Stanley now owns 12,545,572 shares of the company’s stock valued at $6,738,605,000 after acquiring an additional 83,915 shares during the last quarter. Finally, Northern Trust Corp raised its position in shares of Eli Lilly and Company by 3.6% in the 3rd quarter. Northern Trust Corp now owns 10,158,275 shares of the company’s stock worth $5,456,314,000 after acquiring an additional 355,317 shares in the last quarter. Institutional investors and hedge funds own 81.38% of the company’s stock.

Eli Lilly and Company Company Profile

(Get Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

Recommended Stories

Analyst Recommendations for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.